Puberty blocker trial will help reduce harm, says Cass report author

A clinical trial for puberty-blocking drugs targeting gender-questioning children has established a minimum age requirement of 11 years. Dr Hilary Cass, the author of the Cass report, expressed absolute conviction regarding the necessity of this study. She asserted that failing to conduct the trial would result in more children being harmed than if the research proceeded. The initiative aims to provide essential data to help reduce harm for children seeking these specific medical interventions.